Country: Jordan
Language: English
Source: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)
Rasagiline 1 mg
شركة التقدم للصناعات الدوائية - Al-Taqqadom Pharmaceutical Industries
N04BD02
Rasagiline 1 mg
1 mg
28
GENEPHARM S.A/GREECE (اليونان)
21.47 :سعر الجمهور + الضريبة
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. - Keep this leaflet.You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What PARCALIN is and what it is used for. 2. Before you take PARCALIN 3. How to take PARCALIN 4. Possible side effects. 5. How to store PARCALIN 6. Further information. 1. WHAT PARCALIN IS AND WHAT IT IS USED FOR: PHARMACOTHERAPEUTIC GROUP: Anti-Parkinson-Drugs, Monoamine oxidase -B inhibitors, ATC code: N04BD02. THERAPEUTIC INDICATIONS: PARCALIN is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations. 2. BEFORE YOU TAKE PARCALIN: A. DO NOT TAKE PARCALIN IN: - Hypersensitivity to the active substance or to any of the excipients. - Concomitant treatment with other monoamine oxidase (MAO) inhibitors (including medicinal and natural products without prescription e.g. St. John's Wort) or pethidine. At least 14 days must elapse between discontinuation of Rasagiline and initiation of treatment with MAO inhibitors or pethidine. - In patients with severe hepatic impairment. B. TAKE SPECIAL CARE WITH PARCALIN: - The concomitant use of Rasagiline and fluoxetine or fluvoxamine should be avoided. At least five weeks should elapse between discontinuation of fluoxetine and initiation of treatment with Rasagiline. At least 14 days should elapse between discontinuation of Rasagiline and initiation of treatment with fluoxetine or fluvoxamine. - Impulse control disorders (ICDs) can occur in patients treated with dopamine agonists and/or dopaminergic treatments. Similar reports of ICDs have also been received post-market Read the complete document